Review of Immune-Related Adverse Events in Prostate Cancer Patients Treated with Ipilimumab: MD Anderson Experience

Targeting a T cell inhibitory checkpoint with the anti-CTLA-4 monoclonal antibody, ipilimumab, represents a scientific breakthrough in immunotherapy for the treatment of cancer. However, ipilimumab therapy is also associated with unique side effects, known as immune-related adverse events (irAEs), w...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncogene
Glavni autori: Gao, Jianjun, He, Qiuming, Subudhi, Sumit, Aparicio, Ana, Zurita-Saavedra, Amado, Lee, Da Hyun, Jimenez, Camilo, Suarez-Almazor, Maria, Sharma, Padmanee
Format: Artigo
Jezik:Inglês
Izdano: 2015
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4530091/
https://ncbi.nlm.nih.gov/pubmed/25659583
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2015.5
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items